Purpose: Little is known about the association between myeloid-derived suppressor cell (MDSC) subsets and various chemokines in patients with renal cell carcinoma (RCC) or the factors that draw MDSC into tumor parenchyma.
Introduction
Renal cell carcinoma (RCC) accounted for 3.8% of newly diagnosed cancers in the United States in 2014, with close to 64,000 new cases diagnosed (SEER data), which indicates a consistent increase in the incidence rate since 1975 (1) . The discovery that biallelic loss of the von Hippel Lindau (VHL) tumor suppressor gene results in increased transcription of growth factors involved in RCC tumorigenesis has resulted in a major paradigm shift in the landscape of RCC treatment, with the development and subsequent approval of several targeted therapies (2) . It is well established that tumor-mediated immunosuppression of the microenvironment and immunoevasion contribute to decreased clinical efficacy of immune and targeted therapy (3) (4) (5) . Along with checkpoint blockade of T-cell function (6) , multiple cell types are involved in tumor-mediated immunosuppression, including type 2 natural killer T (NKT) cells, tumor-associated macrophages (TAM), regulatory T cells (Treg), and myeloid-derived suppressor cells (MDSC; refs. 7, 8) . MDSC are a heterogeneous cell population that is thought to play a major role in tumor-mediated immunoevasion; they arise from myeloid progenitor cells that fail to differentiate into mature dendritic cells, granulocytes, or macrophages and are distinguished by the capacity to suppress T-cell and NK cell function (8, 9) . That MDSC use several mechanisms to suppress antitumor immunity has been demonstrated both in vitro and in vivo. These mechanisms include cysteine sequestration to decrease proliferation, activation, and differentiation of T cells (8) , depletion of L-arginine to arrest T cells in mitosis (10) , induction of FoxP3 þ Treg cells (11) , downregulation of CD4 and CD8 T-cell homing to lymph nodes, and conversion of antitumor M1 cells into tumor-promoting M2 cells (12) . MDSC also promote the tumor vasculature via their production of different angiogenic proteins (13, 14) . MDSC in humans are broadly characterized as expressing CD33 , and multiple MDSC populations have been described in patients with solid tumors. Polymorphonuclear MDSC (PMN-MDSC) additionally express CD15 and are CD14-negative, whereas monocytic MDSC (M-MDSC) express CD14 and not CD15. Immature MDSC (I-MDSC) express neither CD14 nor CD15 (8, 15) .
Peripheral MDSC levels are significantly increased in patients with cancer and correlate with metastatic burden, clinical cancer stage, and outcome. In a study of 106 patients with solid malignancies (although this did not include patients with RCC), circulating MDSC correlated with clinic stage and tumor burden (16) . While PMN-MDSC, M-MDSC, and I-MDSC have been described in patients with RCC, PMN-MDSC are the dominant population in peripheral blood of many different types of cancer, including RCC (17, 18) . A recent study identified 6 MDSC phenotypes in patients with RCC, 5 of which were increased in the periphery compared with healthy donors; the monocytic and PMN-MDSC subtypes correlated with overall survival (19) . Indeed, of all the described MDSC subsets, only 3 have been shown to correlate with clinical outcomes in patients with cancer (20) . Two studies (one in gastrointestinal cancers and one in breast cancer) have shown that increasing levels of CD33 þ HLA-DR À CD11b þ MDSC in the periphery correlate with decreased overall survival (OS; refs. 21, 22) . M-MDSC levels have also been shown to inversely correlate with OS (19) and have been described as an independent risk factor for recurrence in hepatocellular carcinoma (23) . M-MDSC frequency has also been correlated with median progressionfree survival (PFS) in non-small cell lung cancer (24) . PMN-MDSC have been associated with decreased OS time in gastric cancer (24) and in RCC (19) . All of the aforementioned studies pertained only to peripheral MDSC; to our knowledge, no correlation has been made between intratumoral MDSC levels and recurrence-free survival (RFS).
MDSC are induced by chronic inflammation, and inflammatory factors, such as IL6 (25) , IL1b (26, 27) , GM-CSF (28), S100A8/S9A, and prostaglandin E2 (29) , have been shown to promote MDSC accumulation. While associations have been shown between MDSC and various chemokines in the periphery of murine and human cancer hosts, little is known about the factors that draw MDSC directly into the tumor parenchyma, including human RCC.
The chemokine receptor CXCR2 is a key mediator of neutrophil migration (30, 31) , and its ligands, IL8 and CXCL5, have been shown to be chemoattractants for PMN-MDSC (32) (33) (34) (35) (36) (37) . CXCR2 is known to be an important chemokine receptor that directs the recruitment of tumor promoting leukocytes into tissue and the inhibition of this receptor significantly suppresses inflammation-driven and spontaneous tumorigenesis (38, 39) . In established murine tumors, blocking of CXCR2 using cxcr2 À/À mice or by treating with cxcr2 antibodies/antagonists promotes tumor regression and enhances anti-PD1 efficacy of blockade-mediated immunotherapy (32, 40) . Mip-1a is a ligand of CCR5, which is known to be involved in acute inflammation and recruitment and activation of neutrophils (33) (34) (35) . Finally, MCP-1 is a ligand of CCR2, which is known to recruit CD11bGr1 þ MDSC into tumors (41) . Little is known about factors that draw I-MDSC into human tumor parenchyma. In addition, it is known that IL1b induces inflammation, leading to the production of chemoattractants for MDSC, including PMN-MDSC, such as IL8 (42) . Here, we analyzed the relationship between circulating or intratumoral levels of MDSCs and tumor grade, stage, and RFS in patients with RCC. In addition, we determined whether a correlation exists between these parenchymal/peripheral blood MDSC subsets and levels of IL1b, IL8, CXCL5, Mip-1a, MCP-1, and Rantes in the parenchyma and peripheral blood in patients with primary RCC tumors, before patients receiving any treatment, to elucidate some of the factors that might promote MDSC accumulation, particularly the PMN-MDSC subset, as it is the largest population in patients with RCC. In addition, the expression of the chemokine receptor CXCR2 on human and mouse PMN-MDSC was examined along with testing the possibility that CXCR2 þ myeloid cells promote tumor growth
Materials and Methods

Tumor lysates
Primary RCC tumor samples were collected from 48 patients prior to nephrectomy, in accordance with an institutional IRBapproved protocol. Samples were divided and a portion of the tumor was flash-frozen to make lysates using the Fastprep-24 (MP Biomedicals) according to the manufacturer's manual. Briefly, tumor tissue was placed in Lysing Matrix D tubes with RIPA Buffer (Thermo Scientific) and protease inhibitor (Sigma) and Halt Phosphatase inhibitors (Thermo Scientific), incubated and processed in the FastPrep-24. The lysates were then aliquoted and frozen at À80 C.
Phenotype analysis of MDSC subsets from tumor Phenotyping of MDSC was performed on fresh tumor samples. Using flow cytometry, we phenotyped PMN-MDSC, M-MDSC, and I-MDSC from the parenchyma of 48 RCC nephrectomy samples ( Fig. 1 (36, 37) . CXCR2 is a member of the CXC chemokine receptor family binding several chemokines such as IL8 that are involved in inflammation and is strongly associated with neutrophil attraction (43) .
To assess the morphology of MDSC in RCC tumors, MDSC preparation from the percoll gradient was stained with markers for MDSC (CD33, HLA-DR, CD15, and CD14), and individual subsets were then isolated by high-speed cell sorting (Aria FACS). Cytospins were made and then stained with Diff-Quik staining solution.
Phenotype analysis of MDSC subsets from peripheral blood Peripheral blood was obtained prior to surgery from 22 of the 48 patients from whom we had tumor samples, in addition to 33 patients with metastatic disease for whom we did not have tumor tissue. Fifteen controls were available from healthy donors. All samples were obtained in accordance with our IRB protocol. Patient blood was subjected to Ficoll Hypaque density centrifugation, and the buffy layer containing peripheral blood mononuclear cells, including MDSC, was stained with the same antibodies as the tumor for flow cytometric analysis (see above).
The FACS data are presented as the percentage of MDSC subsets in the peripheral blood mononuclear cell (PBMC) buffy layer following Ficoll Hypaque density centrifugation. The percentage of MDSC subsets in the tumor is calculated from the single-cell suspension after digestion of tumor and percoll gradient centrifugation.
Chemokine and IL1b levels from tumor and peripheral blood ELISA (R&D Systems) was used to quantitate levels of IL1b, IL8, CXCL5, Mip-1a, MCP-1, and Rantes in tumor lysates. Plasma was available from 20 of the 48 patients from whom we had tumor samples, and 15 healthy controls. ELISA (R&D systems) was used to measure levels of IL1b, IL8, CXCL5, Mip-1a, MCP-1, and Rantes in plasma. A protein assay (Pierce BCA Protein Assay, Thermo Scientific) was done on both parenchymal and peripheral blood samples to ensure equal amounts of protein were aliquoted in each well. Manufacturer instructions were followed for the ELISA.
Mouse experiments
Renca cells (1 Â 10 6 ) were injected subcutaneously into Balb/c mice. After 14 days, tumor-bearing mice were treated for 21 days with CXCR2 antagonist (40 mg/mouse, once daily intraperitoneally), anti-PD1 antibody (200 mg/mouse, 2 times per week), or the combination. Anti-IL1b treatment (100 mg/mouse, 2 times a week) started 10 days after tumor implantation and lasted 3 weeks. CXCR2 antagonist was purchased from Tocris Bioscience. Anti-PD1 and anti-IL1b antibodies were purchased from Bioexcell. Untreated Renca tumor-bearing mice served as controls. The tumors were harvested, weighed, and digested with enzyme cocktail Collagenase (1 mg/mL, Sigma), DNase (0.1 mg/mL, Sigma), and hyaluronidase (2.5 U/mL, Sigma) and then filtered using 70-mm cell strainers (BD Falcon). The single-cell suspensions were stained with CD4 (eBioscience), CD8, Ly6G, CD11b (all from BD Bioscience), and CXCR2 (R&D Systems) antibodies. The cells were acquired for flow cytometry using a BD FACSCalibur and analysis was done using FlowJo (Treestar).
Statistical methods
Categorical variables were summarized as frequency counts and percentages, measured data as medians and ranges. The Wilcoxon rank-sum and Jonckheere-Terpstra tests were used for the comparison of MDSC between patient groups. Spearman rank correlations were used to assess the association between MDSC and inflammatory factors in tumor samples and blood from patients with RCC. Time to recurrence was measured from the date of nephrectomy to the date of progression on imaging or last follow-up and was analyzed using proportional hazards models. All P values are 2-tailed and performed at a significance level of 0.05. SAS 9.3 software (SAS Institute) was used for all analyses.
Results
Patient characteristics
The present cohort included 48 patients with RCC prior to nephrectomy. Median age was 62.9 years (range: 39-82.8) and 34 patients (70.8%) were male. All included patients (100%) had clear cell carcinoma. Ten patients (20.8%) had grade 2 histology, 28 (58.3%) had grade 3, and 10 (20.8%) grade 4 histology. Twenty-six patients (54.2%) had stage I-II, 15 (31.3%) had stage 3, and 7 patients (14.6%) had metastatic (stage IV) disease at the time of nephrectomy (Table 1) . Of the 7 patients with metastases, 7 had lung, lymph node, or adrenal involvement, 3 had liver metastases, and 1 each had bone or stomach metastases. Peripheral blood was available from 22 of the 48 patients, and blood was available from 33 patients who did not have tumor samples available. No patient had received any systemic anticancer treatment prior to nephrectomy. The peripheral blood analysis of MDSC subsets in patients with RCC was compared to the same populations in the PBMC fraction from healthy controls.
MDSC subset levels are increased in the peripheral blood and tumor of patients with RCC relative to MDSC levels detected in the blood from normal healthy donors Figure 1A shows the gating strategy and analysis of the 3 major MDSC subsets based on staining for CD33, HLA-DR, CD15, and CD14. Compared with healthy donor PBMC (n ¼ 15), the numbers of PMN-MDSC and I-MDSC are significantly increased in the blood and tumor (Fig. 1B) . The morphology of the 3 subsets is also shown.
Peripheral blood was available from 55 patients and 15 normal controls ( Table 2 , with MDSC subsets expressed as medians). Comparing MDSC subset levels in each cohort, we found that total MDSC are 3.5% in patients versus 1.8% in controls (a 1.94-fold increase, P ¼ 0.002). In addition, PMN-MDSC were 47.5-fold elevated in patients with RCC compared with controls (1.9% vs. 0.04%, respectively; P < 0.001). I-MDSC were also elevated in patients compared with controls (2.0% vs. 1.09%, a 1.83-fold increase; P ¼ 0.003). Levels of M-MDSC did not differ significantly between the 2 cohorts. Furthermore, levels of MDSC did not differ when comparing limited stage (stage I, II, and III) to patients with stage IV disease.
Peripheral blood PMN-MDSC levels correlate with tumor grade
In our analysis, increasing peripheral levels of PMN-MDSC correlate with higher tumor grade (P ¼ 0.006). As with M-MDSC levels in patients versus controls, we did not find a correlation between peripheral M-MDSC levels and tumor grade, nor did we find a correlation between peripheral levels of total MDSC or I-MDSC and grade. Parenchymal levels of MDSC subsets did not correlate with tumor grade. No MDSC subset in the peripheral blood correlated with tumor stage.
Peripheral MDSC subset data and RFS data were available from 16 patients with stage I to III disease. Likewise, tumor samples were available from 34 patients with limited stage (stage I-III) disease. We used 48 patients for immune analysis but 8 of those have limited follow-up time, so we excluded them from the RFS analysis. The tumor PMN-MDSC population was found to be marginally significant for RFS (P ¼ 0.0505). With our current sample size, other MDSC subsets in the tumor did not correlate with RFS, nor did peripheral MDSC correlate with RFS. 
MDSC subsets correlate with certain chemokines and IL1b
We examined RCC tumor tissue for expression of chemokines known to promote the trafficking of PMN-MDSC and neutrophils (IL8, CXCL5, and Mip-1a; refs. [32] [33] [34] [35] . MCP1 levels were examined, as it is known to cause MDSC accumulation in a mouse tumor model (41) . We also examined the expression of IL1b in the tumors, as this inflammatory cytokine is known to induce the production of chemokines like IL8 and CXCL5, thereby indirectly promoting MDSC recruitment (44) .
Here, we show that parenchymal levels of PMN-MDSC have a positive correlation with IL8 (P < 0.001), CXCL5 (P < 0.001), and Mip-1a (P ¼ 0.014; Table 3 ). Intratumor levels of IL1b (P ¼ 0.029) also correlated with PMN-MDSC levels in tumor tissue. Rantes (CCL5) levels did not correlate with MDSC accumulation. In addition, we show that levels of I-MDSC correlate positively with IL8 (P ¼ 0.033) and CXCL5 (P ¼ 0.008), but not IL1b (Table 3) .
The analysis of blood MDSC, chemokines, and IL1b levels revealed that total MDSC correlated with IL1b plasma levels (P ¼ 0.003) and that PMN-MDSC levels trended toward correlation which did not reach statistical significance (Table 3 ). Blood M-MDSC and I-MDSC subsets did not correlate with any of the chemokines or interleukins we analyzed (Table 3) . We did not find any significant differences between levels of IL1b, IL8, CXCL5, Mip-1a, MCP-1, and Rantes in the blood of patients versus normal controls (data not shown).
Treatment of mice bearing Renca tumors with CXCR2 antagonist enhanced the efficacy of anti-PD1 therapy
Because intratumor levels of PMN-
) correlated with intratumor levels of IL8 and CXCL5, we tested these cells for their expression of CXCR2 which binds IL8 and CXCL5 and is a prominent chemokine receptor expressed on neutrophils and PMN-MDSC (Fig. 2D) . Analysis of 15 localized patients with RCC demonstrated that 50% of the intratumoral PMN-MDSC expressed CXCR2. Further analysis showed that PMN-MDSC from 10 patients showed greater than 47% expression (47%-100%), one patient had 27% expression, whereas only 4 patients displayed low expression (<10%). The analysis of intratumor PMN-MDSC (Ly6G þ CD11b þ ) in mice bearing the renal tumor cell line RENCA demonstrated that approximately 20% to 25% expressed CXCR2, which is somewhat less than the value expressed by human PMN-MDSC (Fig. 2) . None of the Ly6G
À
CD11b
þ monocytic MDSC expressed CXCR2.
Because some PMN-MDSC express the chemokine receptor CXCR2, we wanted to test whether antagonizing CXCR2 would reduce tumor growth and simultaneously enhance T-cell response in the tumor. As part of this experiment, we also tested whether combining treatment using the CXCR2 antagonist with anti-PD1 antibody would improve outcome. Similar to others (32), treatment of tumor-bearing mice with anti-PD1 antibody once tumors are well established only affords modest protection (Fig. 2) . However, treating RENCA-bearing mice with a CXCR2 antagonist along with anti-PD1 antibody improved the efficacy of the checkpoint blockade antibody(P 0.05; Fig. 2A ), whereas treatment with the antagonist alone had minimal impact on tumor weight. Interestingly, CXCR2 antagonist alone or when combined with anti-PD1 antibody did not reduce the number of PMN-MDSC in the tumor, suggesting that the antagonist may block the suppressive function of the MDSC. However, combination treatment did increase the infiltration of both CD4 þ T cells (P ¼ 0.009) and CD8 þ T cells (P ¼ 0.058), which coincided with a reduction in tumor weight.
IL1b blockade inhibits PMN-MDSC recruitment and delays tumor progression
IL1b is a master regulator of chemokine/cytokine expression (45) and is known to promote MDSC accumulation in the periphery; however, less is known on its impact on intratumoral MDSCs (42) . Given our data with RCC cancer patient samples that showed a correlation between MDSC levels in the tumor and the concentration of intratumoral IL1b along with select chemokines (IL8 and CXCL5), we used the Renca tumor model to test whether blocking IL1b activity would impact MDSC subset levels, concentration of select chemokines, and tumor growth. Anti-IL1b blocking antibody treatment caused a dramatic reduction in PMN-MDSC and M-MDSC in the peripheral blood (P ¼ 3.46E-05 and 0.0002, respectively); however, only the PMN-MDSC subset was significantly reduced in the tumor (P ¼ 0.010; Fig. 3A) . ELISA of serum levels of KC, the homolog for human IL8 and CXCL5 (LIX), showed elevated concentrations of both chemokines in sera of Renca-bearing mice compared with sera from non-tumor-bearing mice. In addition, anti-IL1b treatment significantly reduced levels of both chemokines (Fig. 3B ) that corresponded to the reduction in PMN-MDSC, in both the blood and tumor (Fig. 3A) . Moreover, this relative short-term treatment with anti-IL1b antibody also caused a significant reduction in total tumor cellularity (Fig. 3) .
Discussion
In this study, we compared MDSC subset levels in the peripheral blood of 55 patients with RCC versus 15 controls. We found that total MDSC are elevated in patients versus controls, as are PMN-MDSC and I-MDSC. These findings support those of several other groups (19, 21, 22) . Levels of M-MDSC did not differ (24), and Walter and colleagues demonstrated that M-MDSC are associated with decreased OS in RCC (19) . PMN-MDSC in the periphery of patients with RCC also correlated with increasing tumor grade. While several studies have shown a correlation between peripheral MDSC levels and patient outcomes, to our knowledge, ours is the first to show a correlation between MDSC subset levels and tumor grade in RCC. We did not find a correlation between parenchymal MDSC levels and grade, which may be due to inherent variability within the parenchyma. Small tissue samples are unlikely to be representative of the entire tumor.
In this study, we sought to assess whether parenchymal levels of MDSC correlate with RFS. Tumor samples were available from 34 patients with limited stage (stage I-III) disease. PMN-MDSC marginally correlated with RFS in patients with limited stage disease (P ¼ 0.0505). Total MDSC, M-MDSC, and I-MDSC did not significantly correlate with RFS in limited stage disease, this may be because our sample size was too small to detect a significant difference (17) , or because of wide variability in the immune infiltrate within the tumor. To the best of our knowledge, only two published studies have explored the clinical significance of intratumoral MDSCs (20, 48) . In this study, Cui and colleagues demonstrated that patients whose ovarian cancer samples were CD33 þ high (by immunohistochemical staining) had decreased OS compared with patients with CD33 þ low samples (48) .
PMN-MDSC derived from the peripheral blood of patients with RCC have been shown to suppress T-cell production of IFNg and T-cell proliferation during in vitro coculture experiments, whereas neutrophils from healthy donors are not suppressive (Ko and colleagues, manuscript in preparation). The mechanism of suppression by PMN-MDSC is partly dependent on the arginase pathway (10, 17, 18, 49) . We found that PMN-MDSC, but not healthy donor neutrophils, are angiogenic, as demonstrated by their capacity to enhance tumor blood vessel formation following co-injection with an RCC cell line (ACHN) in a xenograft model using NOD/scid mice (Ko and colleagues, manuscript in preparation). Thus, these findings support the idea that PMN-MDSC have the potential to block the development of an effective antitumor immunity, thereby promoting tumor progression. Additional support for this concept comes from a study by Highfill and colleagues showing that PMN-MDSC (Ly6G 
Cellularity in tumor
Anti-IL1β the idea that CXCR2 þ PMN-MDSC are important in reducing the antitumor activity of anti-PD1 antibody and promoting tumor progression.
A major focus of this study is to assess whether parenchymal levels of MDSC subsets correlate with certain chemokines and ILb. Indeed, we found that PMN-MDSC correlated with intratumor levels of IL1b, IL8, CXCL5, and Mip-1a. These data suggest that these chemokines and IL1b promote accumulation of PMN-MDSC in the parenchyma of the RCC host. CXCR2, the receptor for IL8 and CXCL5, was expressed in more than 50% of PMN-MDSC. Although the data are associative, they suggest that this MDSC subset is drawn into the RCC tumor parenchyma by these cytokines in the tumor milieu. Indeed, CXCL5 and IL8 have been shown to be chemokines to PMN-MDSC (38) .
Rantes (CCL5) did not correlate with MDSC accumulation, which was not a surprising finding given that it is primarily chemotactic for eosinophils and basophils (50) . Furthermore, levels of I-MDSC correlated with IL8 and CXCL5, but not IL1b. In peripheral blood, the only significant association was between total MDSC and IL1b, although there was a trend toward an association between blood levels of IL1b and blood-derived PMN-MDSC (Table 3) .Thus, in blood and tumor, IL1 levels correlated with MDSC levels. Other blood MDSC subsets did not correlate with any of the chemokines or interleukins we analyzed, and this may be a function of sample size; we were unable to detect significant differences between chemokine and IL1b between blood levels in patients and normal controls (data not shown). Other potential causes could include sample stability, as samples were frozen. Some of the normal controls may have had comorbidities or subclinical viral infections that could have caused elevations in chemokines. The pivotal role of IL1b in regulating the mobilization and recruitment of PMN-MDSCs was further corroborated by our studies using a blocking antibody. Decreases in the levels of PMN-MDSCs in both periphery and tumor correlated with reduced levels of CXCL5 and IL8 and a reduction in total tumor cellularity in the Renca model. Similarly, a recent study showed that in a prostate cancer model, a CXCR2 antagonist reduced tumor weight and prolonged survival, and anti-CXCL5 Ab or CXCR2 inhibitor reduced MDSC migration in vitro. In a colon cancer murine model, mice with increased levels of IL8 had increased immature myeloid cells (51) .
The chemokine receptor CXCR2 is a key mediator of neutrophil migration. Its ligands, IL8 and CXCL5, have been shown to be chemoattractants for PMN-MDSC (32, 38) . IL8 is a proinflammatory chemokine that is thought to promote neutrophil chemotaxis and degranulation, and increased expression of IL8 and/ or its receptors has been shown in cancer cells, endothelial cells, and TAMs, suggesting it may play a significant role in the regulation of the tumor microenvironment (52) .
Indeed, IL8, in addition to IL6 and TNFa, has been shown to be significantly increased in RCC tissue and its expression dependent on the degree of malignancy (53) . Furthermore, higher levels of IL8 have been associated with decreased survival (9 vs. 17 months, P ¼ 0.0371; ref. 53) , and IL8 has been shown to be an independent predictor of OS (54) . Here, we show that parenchymal levels of IL8 correlate with increased total MDSC (P < 0.001), PMN-MDSC (P < 0.001), and I-MDSC (P ¼ 0.033). While these data are associative, it again suggests that IL8 plays an important role in immunomodulation of the tumor microenvironment. We found a similar association between parenchymal levels of CXCL5 and increased total MDSC (P < 0.001), PMN-MDSC (P < 0.001), and I-MDSC (P ¼ 0.008), which was not surprising, given that CXCL5 and IL8 are both ligands of CXCR2, and we show that PMN-MDSC in RCC tissue express this chemokine receptor. The correlation of I-MDSC with IL8 and CXCL5 is especially interesting, given that little is known about the factors that draw I-MDSC into the tumor parenchyma. Interestingly, CXCL5 expression has been associated with decreased survival in a number of human tumors (55) , and IL8 levels were recently shown to correlate with PFS and OS in mRCC (ref. 54 ; for CXCL5, these were studies on tumor parenchyma, whereas with IL8 this was a study on circulating protein).
Other chemokine receptors such as CCR5 likely play a role in trafficking and activation of MDSC infiltrating RCC. Indeed, we found that parenchymal levels of total MDSC and PMN-MDSC correlated with levels of Mip-1a, suggesting that perhaps PMN-MDSC or a subpopulation of these cells express CCR5 in addition to CXCR2. FACS analysis of murine PMN-MDSC derived from CT26 IL1b-expressing tumors showed dual expression of CXCR2 and CCR5 on a subset of PMN-MDSC (Tannenbaum, manuscript in preparation). It is well established that IL1b induces production of chemoattractants for PMN-MDSC, such as IL8, and we found a positive correlation between total intratumor levels of MDSC, PMN-MDSC, and IL1b.
While we did not find increased levels of chemokines or IL1b in the blood of patients compared with controls (perhaps due to our small sample size), increased IL8 has been described in the serum of patients with RCC compared with controls (56) (57) (58) , and IL8 has repeatedly been linked to sunitinib resistance (59, 60) . Similarly, high serum concentrations of IL1b and MCP-1 have been described in larger cohorts of patients with RCC (57), and IL1b levels have been shown to be an independent risk factor for increased risk of recurrence and decreased overall survival in limited stage RCC (61) .
Our study has several limitations; our small sample size may have led to type II error in some instances, such as the inability to discern associations between peripheral/parenchymal M-MDSC and grade, stage, or RFS, or the difference between chemokine levels in the serum of patients versus controls. Furthermore, although MDSC in tumor were quantitated with freshly isolated tumor tissue, a few of the samples used for chemokine analysis had been frozen whole, then thawed, which may have led to intersample variability. Despite these limitations, our results clearly indicate that PMN-MDSC and I-MDSC are significantly increased in the blood and tumor of RCC patients, and that peripheral blood PMN-MDSC, correlate with tumor grade. Finally, we show that parenchymal levels of PMN-MDSC have a positive correlation with intratumor levels of IL1b, IL8, CXCL5, and Mip-1a, suggesting that these chemokines may attract PMN-MDSC and I-MDSC into the parenchyma of the RCC host. The increased intratumoral expression of the CXCR2 ligands (IL8 and CXCL5), the CCR5 ligand Mip-1a, along with the inflammatory cytokine IL1b likely promote the accumulation of PMN-MDSC and I-MDSC into RCC tissue, and their presence in the tumor likely promotes T-cell-mediated suppression and tumor angiogenesis.
Conclusion
Our study provides potential new targets for the risk stratification of patients with limited stage renal carcinoma, in addition to elucidating a possible association between MDSC subsets and chemokine-induced migration into the tumor tissue. Although chemokine recruitment of PMN-MDSC had been previously suggested, little is known about the recruitment of I-MDSC and their suppressive/angiogenic activity. Targeting CXCR2, CCR5, and their ligands as well as IL1b may reduce MDSC number and function, which could enhance the efficacy of immunotherapy and targeted therapy approaches, including immune checkpoint blockade, in patients with RCC. Further research is required in larger cohorts.
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